|  |  |
| --- | --- |
|  |  |
| **#** | **Cytokine** | **Category** | **Full name**  | **Alternative name** |
| **1** | **MIP-1a** | Chemokine | Macrophage inflammatory protein 1a | CCL3 |
| **2** | **MIP-1b** | Chemokine | Macrophage inflammatory protein 1b | CCL4 |
| **3** | **MIP-3a** | Chemokine | Macrophage inflammatory protein 3a | CCL20 |
| **4** | **IL8** | Chemokine | Interleukin-8 |   |
| **5** | **Fractalkine** | Chemokine | Fractalkine | CX3CL1 |
| **6** | **ITAC** | Chemokine | Interferon-inducible T-cell alpha chemoattractant | CXCL11/IP-9 |
| **7** | **IL-2** | Homeostatic | Interleukin-2 |   |
| **8** | **IL-7** | Homeostatic | Interleukin-7 |   |
| **9** | **GM-CSF** | Homeostatic/Proinflammatory | Granulocyte-macrophage colony-stimulating factor |   |
| **10** | **IL-1b** | Pro-inflammatory | Interleukin-1 beta |   |
| **11** | **IL-6** | Pro-inflammatory | Interleukin-6 |   |
| **12** | **TNF** | Pro-inflammatory | Tumour necrosis factor |   |
| **13** | **IL17a** | Pro-inflammatory (Th17) | Interleukin-17 |   |
| **14** | **IL23** | Pro-inflammatory (Th17) | Interleukin-23 |   |
| **15** | **IL10** | Regulatory | Interleukin-10 |   |
| **16** | **IL21** | Regulatory | Interleukin-21 |   |
| **17** | **IFNγ** | Type 1 | Interferon-gamma |   |
| **18** | **IL12** | Type 1 | Interleukin-12 |   |
| **19** | **IL13** | Type 2 | Interleukin-13 |   |
| **20** | **IL4** | Type 2 | Interleukin-4 |   |
| **21** | **IL5** | Type 2 | Interleukin-5 |   |

**Supplementary Table 1.** Description of the cytokines assessed by multiplex ELISA in the serum of Mongolian adolescents.

**Supplementary Table 2.** Baseline Characteristics of Children in the Vitamin D Supplementation and Placebo groups.1

|  |  |  |  |
| --- | --- | --- | --- |
| **Participant characteristic** | **Entire cohort (n=58)** | **Placebo (N=30)** | **Supplemented group (N=28)** |
| **Median age (IQR)** | 14.0 (13.0-15.0) | 13.0 (13.0-15.0) | 14.0 (13.0-15.0) |
| **Male sex, n (%)** | 28 (48.0) | 15 (50.0) | 13 (46.0) |
| **Housing, living in a ger, n(%)** | 30 (52%) | 18 (60%) | 12 (42%) |
| **Consuming vitamins or minerals outside the study, n(%)** | 27 (47%) | 16 (53%) | 11 (39%) |
| **Mean height-for-age z score (CI)** | -0.66 (-0.949/-0.360) | -0.46 (-0.868/-0.059) | -0.85 (-1.30/-0.410) |
| **Mean height-for-BMI z score (CI)** | -.26 (-0.246/-0.214) | 0.06 (-0.266/-0.380) | -0.09 (-0.439/0.255) |
| **Mean N of people residing with (CI)** | 5.07 (4.66-5.47) | 5.37 (4.72-6.01) | 4.75 (4.26-5.24) |
| **Median serum 25(OH)D level, nmol/L (IQR)** | 13.6 (10.0-21.7) | 13.6 (10.0-22.9) | 13.7 (10.0-20.7) |

1 None of the variables were significantly different between the vitamin D supplemented and placebo groups at baseline,

BMI= body mass index, CI= confidence interval